Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
NCT00355082
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
226
Enrollment
INDUSTRY
Sponsor class
Conditions
Epilepsy, Partial
Interventions
DRUG:
lamotrigine, 300 mg/day
DRUG:
lamotrigine, 250 mg/day
Sponsor
GlaxoSmithKline